Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Proia

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Oncotarget|October 26, 2016
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer modelsEgor Bobrov, Natalia Skobeleva, Diana Restifo, et al.
Cancers|May 27, 2015
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma CellsRoberto Gomez-Casal, Chitralekha Bhattacharya, Michael W Epperly, et al.
Haematologica|September 12, 2000
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoringG Meloni, A Proia, F Mauro, et al.
Clinical Colorectal Cancer|December 3, 2014
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerAndrea Cercek, Jinru Shia, Marc Gollub, et al.
International Journal of Oncology|November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionSuqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Leukemia & Lymphoma|October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the bloodAmber Shatzer, Mir A Ali, Mayra Chavez, et al.
Molecular Cancer Therapeutics|March 6, 2026
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumoursAzadeh C Bashi, Theresa A Proia, Mandy Lawson, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 22, 2013
Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013A Carattoli, D Fortini, R Galetti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 5, 2002
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapyRohit Talwani, Oluwatoyin M Falusi, Carlos F Mendes de Leon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2018
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell TumorsCheryl A London, Jaime Acquaviva, Donald L Smith, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Oncotarget|October 26, 2016
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer modelsEgor Bobrov, Natalia Skobeleva, Diana Restifo, et al.
Cancers|May 27, 2015
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma CellsRoberto Gomez-Casal, Chitralekha Bhattacharya, Michael W Epperly, et al.
Haematologica|September 12, 2000
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoringG Meloni, A Proia, F Mauro, et al.
Clinical Colorectal Cancer|December 3, 2014
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerAndrea Cercek, Jinru Shia, Marc Gollub, et al.
International Journal of Oncology|November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionSuqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Leukemia & Lymphoma|October 1, 2016
Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the bloodAmber Shatzer, Mir A Ali, Mayra Chavez, et al.
Molecular Cancer Therapeutics|March 6, 2026
Capivasertib combines with trastuzumab deruxtecan to enhance anti-tumour activity in HER2-positive and HER2-low tumoursAzadeh C Bashi, Theresa A Proia, Mandy Lawson, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 22, 2013
Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013A Carattoli, D Fortini, R Galetti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 5, 2002
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapyRohit Talwani, Oluwatoyin M Falusi, Carlos F Mendes de Leon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2018
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell TumorsCheryl A London, Jaime Acquaviva, Donald L Smith, et al.
Pageof 9